157 related articles for article (PubMed ID: 21110807)
1. The role of survivin for radiation oncology: moving beyond apoptosis inhibition.
Rödel F; Reichert S; Sprenger T; Gaipl US; Mirsch J; Liersch T; Fulda S; Rödel C
Curr Med Chem; 2011; 18(2):191-9. PubMed ID: 21110807
[TBL] [Abstract][Full Text] [Related]
2. Survivin inhibition and DNA double-strand break repair: a molecular mechanism to overcome radioresistance in glioblastoma.
Reichert S; Rödel C; Mirsch J; Harter PN; Tomicic MT; Mittelbronn M; Kaina B; Rödel F
Radiother Oncol; 2011 Oct; 101(1):51-8. PubMed ID: 21852011
[TBL] [Abstract][Full Text] [Related]
3. Survivin as a prognostic/predictive marker and molecular target in cancer therapy.
Rödel F; Sprenger T; Kaina B; Liersch T; Rödel C; Fulda S; Hehlgans S
Curr Med Chem; 2012; 19(22):3679-88. PubMed ID: 22680927
[TBL] [Abstract][Full Text] [Related]
4. Radiation-induced survivin nuclear accumulation is linked to DNA damage repair.
Capalbo G; Dittmann K; Weiss C; Reichert S; Hausmann E; Rödel C; Rödel F
Int J Radiat Oncol Biol Phys; 2010 May; 77(1):226-34. PubMed ID: 20394854
[TBL] [Abstract][Full Text] [Related]
5. Survivin as a target for new anticancer interventions.
Zaffaroni N; Pennati M; Daidone MG
J Cell Mol Med; 2005; 9(2):360-72. PubMed ID: 15963255
[TBL] [Abstract][Full Text] [Related]
6. The role of survivin for radiation therapy. Prognostic and predictive factor and therapeutic target.
Capalbo G; Rödel C; Stauber RH; Knauer SK; Bache M; Kappler M; Rödel F
Strahlenther Onkol; 2007 Nov; 183(11):593-9. PubMed ID: 17960333
[TBL] [Abstract][Full Text] [Related]
7. Torc1/Torc2 inhibitor, Palomid 529, enhances radiation response modulating CRM1-mediated survivin function and delaying DNA repair in prostate cancer models.
Gravina GL; Marampon F; Sherris D; Vittorini F; Di Cesare E; Tombolini V; Lenzi A; Jannini EA; Festuccia C
Prostate; 2014 Jun; 74(8):852-68. PubMed ID: 24715588
[TBL] [Abstract][Full Text] [Related]
8. A radiosensitizing effect of artesunate in glioblastoma cells is associated with a diminished expression of the inhibitor of apoptosis protein survivin.
Reichert S; Reinboldt V; Hehlgans S; Efferth T; Rödel C; Rödel F
Radiother Oncol; 2012 Jun; 103(3):394-401. PubMed ID: 22560712
[TBL] [Abstract][Full Text] [Related]
9. The SMAC mimetic BV6 sensitizes colorectal cancer cells to ionizing radiation by interfering with DNA repair processes and enhancing apoptosis.
Hehlgans S; Oppermann J; Reichert S; Fulda S; Rödel C; Rödel F
Radiat Oncol; 2015 Sep; 10():198. PubMed ID: 26383618
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic targeting of the survivin pathway in cancer: initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis.
Blanc-Brude OP; Mesri M; Wall NR; Plescia J; Dohi T; Altieri DC
Clin Cancer Res; 2003 Jul; 9(7):2683-92. PubMed ID: 12855648
[TBL] [Abstract][Full Text] [Related]
11. Survivin expression and resistance to anticancer treatments: perspectives for new therapeutic interventions.
Zaffaroni N; Daidone MG
Drug Resist Updat; 2002 Apr; 5(2):65-72. PubMed ID: 12135582
[TBL] [Abstract][Full Text] [Related]
12. Phosphatidylinositol 3-kinase inhibition down-regulates survivin and facilitates TRAIL-mediated apoptosis in neuroblastomas.
Kim S; Kang J; Qiao J; Thomas RP; Evers BM; Chung DH
J Pediatr Surg; 2004 Apr; 39(4):516-21. PubMed ID: 15065019
[TBL] [Abstract][Full Text] [Related]
13. Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer.
Rödel F; Hoffmann J; Distel L; Herrmann M; Noisternig T; Papadopoulos T; Sauer R; Rödel C
Cancer Res; 2005 Jun; 65(11):4881-7. PubMed ID: 15930309
[TBL] [Abstract][Full Text] [Related]
14. The functional repertoire of survivin's tails.
Wheatley SP
Cell Cycle; 2015; 14(2):261-8. PubMed ID: 25607650
[TBL] [Abstract][Full Text] [Related]
15. Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivin.
Kelly RJ; Lopez-Chavez A; Citrin D; Janik JE; Morris JC
Mol Cancer; 2011 Apr; 10():35. PubMed ID: 21470426
[TBL] [Abstract][Full Text] [Related]
16. Treat cancers by targeting survivin: just a dream or future reality?
Coumar MS; Tsai FY; Kanwar JR; Sarvagalla S; Cheung CH
Cancer Treat Rev; 2013 Nov; 39(7):802-11. PubMed ID: 23453862
[TBL] [Abstract][Full Text] [Related]
17. Targeting survivin in cancer therapy.
Pennati M; Folini M; Zaffaroni N
Expert Opin Ther Targets; 2008 Apr; 12(4):463-76. PubMed ID: 18348682
[TBL] [Abstract][Full Text] [Related]
18. The inhibitors of apoptosis (IAPs) as cancer targets.
Hunter AM; LaCasse EC; Korneluk RG
Apoptosis; 2007 Sep; 12(9):1543-68. PubMed ID: 17573556
[TBL] [Abstract][Full Text] [Related]
19. Survivin-Based Treatment Strategies for Squamous Cell Carcinoma.
Santarelli A; Mascitti M; Lo Russo L; Sartini D; Troiano G; Emanuelli M; Lo Muzio L
Int J Mol Sci; 2018 Mar; 19(4):. PubMed ID: 29587347
[TBL] [Abstract][Full Text] [Related]
20. Survivin Modulators: An Updated Patent Review (2011-2015).
Roy K; Singh N; Kanwar RK; Kanwar JR
Recent Pat Anticancer Drug Discov; 2016; 11(2):152-69. PubMed ID: 26924735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
